30 Dec 2002: Update on Eprex® and pure red cell aplasia
			The subcutaneous route is not recommended in chronic renal failure (CRF) patients and only intravenous route should be used in CRF patients, haemodialysis and peritoneal dialysis patients.

			26 Dec 2002: Zafirlukast (Accolate®) and hepatic effects
			Rare cases of symptomatic hepatitis (with or without hyperbilirubinaemia); and hyperbilirubinaemia without other elevated liver function tests have been reported in patients, mostly females, who have received Accolate®.

			16 Sep 2002: Leflunomide (Arava®) and liver toxicities
			Treatment with leflunomide requires careful medical supervision. Leflunomide has a profile of serious reactions including haematological, hepatic, allergic, dermatological and respiratory disorders.

			03 Sep 2002: Association of tamoxifen and uterine sarcoma
			The package insert for Nolvadex® (tamoxifen) were amended to include additional information on the increased rare risk of uterine sarcoma (mostly malignant mixed Mullerian tumours) as well as the previously noted increased risk of endometrial adenocarcinoma.

			28 Aug 2002: Eprex® (Epoetin alfa) and reports of pure red cell aplasia
			Pure red cell aplasia has been reported in some chronic renal failure patients who are using Eprex®, mainly via subcutaneous injection.

			31 Jul 2002: Updated report on sibutramine (Reductil®)
			The HSA updates its advisory on sibutramine (Reductil®, Abbott), an anti-obesity drug, to include information on the recently completed review by the central European Committee for Proprietary Medicinal Products (CPMP).

			23 Jan 2002: Phenylbutazone found in jamu product Serbuk Jarem (Encok)
			Public is advised to avoid the consumption of the jamu product "Sari Alam brand Serbuk Jarem (Encok)". HSA's investigations and analytical tests confirm that this jamu product has been adulterated with a western medicinal ingredient, phenylbutazone.

			15 Jan 2002: Kava-kava health supplements and liver toxicities
			Kava-kava containing products are voluntarily withdrawn by traders in Singapore. This precautionary measure is being taken in the light of the serious liver side effects reported recently in Germany and Switzerland.

			14 Jan 2002: Recall of Hepatitis A Vaccines VAQTA Paediatric Prefilled Syringes
			Some batches of VAQTA Paediatric prefilled syringes containing 25 units/0.5 ml of inactivated Hepatitis A Vaccine are recalled as recent investigations have found some of these syringes with potencies below the product specifications.